Loading
CCND1 (G1/S-specific cyclin-D1) is a protein that switches other genes on and off. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor, a biomarker, a fusion partner and a DNA repair gene, and an approved or late-stage drug is recorded against it. Tied to Breast cancer, Skin cancer, Multiple myeloma and 5 more. This dossier gathers the 0 products (0 approved), 4 trials, 0 pathways and 0 resistance routes in the corpus that involve it, with external identifiers so it can be joined to UniProt, ChEMBL, Open Targets and the rest of biology.
Regulatory component of the cyclin D1-CDK4 (DC) complex that phosphorylates and inhibits members of the retinoblastoma (RB) protein family including RB1 and regulates the cell-cycle during G(1)/S transition. Phosphorylation of RB1 allows dissociation of the transcription factor E2F from the RB/E2F complex and the subsequent transcription of E2F target genes which are responsible for the progression through the G(1) phase. Hypophosphorylates RB1 in early G(1) phase. Cyclin D-CDK4 complexes are major integrators of various mitogenenic and antimitogenic signals. Also a substrate for SMAD3, phosphorylating SMAD3 in a cell-cycle-dependent manner and repressing its transcriptional activity. Component of the ternary complex, cyclin D1/CDK4/CDKN1B, required for nuclear translocation and activity of the cyclin D-CDK4 complex. Location: Nucleus; Cytoplasm; Nucleus membrane (UniProt). Locus 11q13.3 (HGNC).
No product in the corpus is aimed at this target yet.
| Trial | Setting | Result | Products | ||
|---|---|---|---|---|---|
| 3 | Active | A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination With Acalabrutinib (ACP-196) in Subjects With Previously Untreated Mantle Cell Lymphoma | Median progression-free survival 66.4 against 49.6 months (hazard ratio 0.73, p = 0.0160), with no significant overall survival difference (hazard ratio 0.86, p = 0.27). | ||
SHINE NCT01776840 | 3 | Mixed | Aged 65 or over with untreated mantle cell lymphoma: ibrutinib added to six cycles of bendamustine and rituximab, with rituximab maintenance | Median progression-free survival 80.6 against 52.9 months (hazard ratio 0.75, p = 0.01) with no overall survival difference. | |
LyMa NCT00921414 | 3 | Positive | Under 66 at diagnosis with mantle cell lymphoma, after R-DHAP induction and autologous stem-cell transplantation: three years of rituximab maintenance against observation | Four-year event-free survival 79 against 61 per cent (p = 0.001) and improved overall survival with three years of rituximab maintenance after transplantation. | |
| ENRICH | 2/3 | Positive | Aged 60 or over with untreated stage II to IV mantle cell lymphoma: ibrutinib with rituximab against rituximab with R-CHOP or bendamustine | Progression-free survival adjusted hazard ratio 0.69 (p = 0.0034) for ibrutinib with rituximab against immunochemotherapy, driven by the comparison against R-CHOP (0.37) rather than against bendamustine-rituximab (0.91). |
No recorded escape route names this target.
No pathway diagram carries this target as a node.
No companion diagnostic in the registry measures this target.
No model entry for this target yet; check the cancer entries on the models page.
No open questions recorded for this target yet. Suggest one.
Query for this target: (TITLE:"CCND1" OR ABSTRACT:"CCND1" OR TITLE:"cyclin D1" OR ABSTRACT:"cyclin D1" OR TITLE:"G1/S-specific cyclin-D1" OR ABSTRACT:"G1/S-specific cyclin-D1" OR TITLE:"U21B31" OR ABSTRACT:"U21B31" OR TITLE:"BCL1" OR ABSTRACT:"BCL1" OR TITLE:"D11S287E" OR ABSTRACT:"D11S287E") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about CCND1, not a curated reading list.
The dossier as machine-readable JSON, at /api/v1/dossiers/ccnd1.json: identifiers from HGNC, Ensembl, UniProt and ChEMBL, products with status, trials, pathways, hotspots, open questions and assays. The full entity record is in the open API at /api/v1/entities/ccnd1.json. Licence CC BY-NC 4.0.